Cargando…

Selective review and commentary on emerging pharmacotherapies for opioid addiction

Pharmacotherapies for opioid addiction under active development in the US include lofexidine (primarily for managing withdrawal symptoms) and Probuphine®, a distinctive mode of delivering buprenorphine for six months, thus relieving patients, clinicians, and regulatory personnel from most concerns a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ling, Walter, Mooney, Larissa, Zhao, Min, Nielsen, Suzanne, Torrington, Matthew, Miotto, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846315/ https://www.ncbi.nlm.nih.gov/pubmed/24474855 http://dx.doi.org/10.2147/SAR.S22782

Ejemplares similares

Pharmacotherapy of Pain in the Older Population: The Place of Opioids
por: Prostran, Milica, et al.
Publicado: (2016)

Emerging Trend in the Pharmacotherapy of Osteoarthritis
por: Zhang, Wei, et al.
Publicado: (2019)

Role of Appetite-Regulating Peptides in the Pathophysiology of Addiction: Implications for Pharmacotherapy
por: Engel, Jörgen A., et al.
Publicado: (2014)

Opioid Pharmacotherapy for Chronic Noncancer Pain: The American Experience
por: Chapman, C. Richard
Publicado: (2013)

In this Issue: Opioid Addiction
por: Khan, Omar A., et al.
Publicado: (2017)

Differences in addictive beliefs in people with psychostimulant addiction and in opioid addicts
por: Yan, Y., et al.
Publicado: (2022)

The functional sequelae of schizophrenia: consequences of long-term pharmacotherapy and the neurobiology of addiction
por: Falkai, P., et al.
Publicado: (2011)

Payer Policy Behavior Towards Opioid Pharmacotherapy Treatment in Ohio
por: Molfenter, Todd, et al.
Publicado: (2018)

Emerging pharmacotherapies for COVID-19
por: Salvi, Rachana, et al.
Publicado: (2020)

Current and Emerging Pharmacotherapy for Fibromyalgia
por: Tzadok, Roie, et al.
Publicado: (2020)

Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu‐opioid receptor
por: Zhang, Jia‐Jia, et al.
Publicado: (2022)

Opioids, dopamine, stress, and the addictions
por: Kreek, Mary Jeanne
Publicado: (2007)

Chronic pain, opioids and addiction
por: Salduker, Shaquir
Publicado: (2018)

Multifactorial Etiology of Adolescent Nicotine Addiction: A Review of the Neurobiology of Nicotine Addiction and Its Implications for Smoking Cessation Pharmacotherapy
por: Mahajan, Supriya D., et al.
Publicado: (2021)

Evaluation of Risk Behavior in Gambling Addicted and Opioid Addicted Individuals
por: Gorzelańczyk, Edward J., et al.
Publicado: (2021)

Criteria for the establishment of a new behavioural addiction •: Commentary to the debate: “Behavioral addictions in the ICD-11”
por: Gullo, Matthew J., et al.
Publicado: (2022)

Emerging Pharmacotherapies for Diabetic Macular Edema
por: Javey, Golnaz, et al.
Publicado: (2012)

Substitution treatment for opioid addicts in Germany
por: Michels, Ingo Ilja, et al.
Publicado: (2007)

The role of social isolation in opioid addiction
por: Christie, Nina C
Publicado: (2021)

How to prevent opioid abuse and addiction
por: Hwang, Sung Mi
Publicado: (2023)

Use of Pharmacotherapies in the Treatment of Alcohol Use Disorders and Opioid Dependence in Primary Care
por: Lee, Jinhee, et al.
Publicado: (2015)

Pharmacotherapy for opioid dependence in jails and prisons: research review update and future directions
por: Sharma, Anjalee, et al.
Publicado: (2016)

Experiences with Medications for Addiction Treatment Among Emergency Department Patients with Opioid Use Disorder
por: Goldfine, Charlotte E., et al.
Publicado: (2023)

Commentary: Addictions Neuroclinical Assessment: A Neuroscience-Based Framework for Addictive Disorders
por: Ghitza, Udi E.
Publicado: (2017)

Mu Opioid Receptor Gene: New Point Mutations in Opioid Addicts
por: Dinarvand, Amin, et al.
Publicado: (2014)

Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine
por: Noble, Florence, et al.
Publicado: (2019)

Interim opioid agonist treatment for opioid addiction: a systematic review
por: Samsó Jofra, Laura, et al.
Publicado: (2022)

Commentary on Glanz et al.: Longer buprenorphine treatment duration is associated with lower rates of opioid overdose, but can we address barriers to staying in treatment?
por: Nielsen, Suzanne, et al.
Publicado: (2022)

Is combination pharmacotherapy effective for management of fibromyalgia in adults? - A Cochrane Review summary with commentary
por: Rathore, Farooq Azam, et al.
Publicado: (2020)

Current and Emerging Pharmacotherapies for Primary CNS Lymphoma
por: Prodduturi, Prathima, et al.
Publicado: (2012)

Pharmacotherapy for uveitis: current management and emerging therapy
por: Barry, Robert J, et al.
Publicado: (2014)

Emerging pharmacotherapy for cancer patients with cognitive dysfunction
por: Davis, Justin, et al.
Publicado: (2013)

Anesthesia for opioid addict: Challenges for perioperative physician
por: Goyal, Rohit, et al.
Publicado: (2013)

MicroRNAs in opioid addiction: elucidating evolution
por: Wood, Emily J., et al.
Publicado: (2012)

X Chromosome Inactivation in Opioid Addicted Women
por: Vousooghi, Nasim, et al.
Publicado: (2015)

Neurobiology of opioid dependence in creating addiction vulnerability
por: Evans, Christopher J., et al.
Publicado: (2016)

Historical Review: Opiate Addiction and Opioid Receptors
por: Wang, Shaocheng
Publicado: (2018)

On the early-life origins of vulnerability to opioid addiction
por: Levis, Sophia C, et al.
Publicado: (2019)

New Patients in Treatment for Opioid Addiction in Spain
por: Pulido, Jose, et al.
Publicado: (2023)

Erratum: Incorrect Title of the Author. Opioid Pharmacotherapy for Chronic Noncancer Pain: The American Experience
por: Chapman, C. Richard
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i640uqeiu7s0m02c8ivrc05n8q